Spanish pharmaceutical company Grifols reported a more than doubling of net profit in 2025, reaching 402 million euros ($473.96 million) compared to 157 million euros in 2024. The company's revenue grew 7% year-over-year to 7.5 billion euros, while adjusted EBITDA rose to 1.8 billion euros, meeting market expectations. CEO Nacho Abia highlighted the company's successful execution in 2025, noting improvements in free cash flow and balance sheet deleveraging.

Despite the strong financial performance, Grifols has lost approximately 25% of its market value since January 2024 following accusations from short-seller Gotham City Research of earnings overstatement and debt understatement. The company's CFO Rahul Srinivasan expressed confidence in Grifols' differentiated strategy and positioning, emphasizing the company's commitment to margin improvement and continued EBITDA growth.

The financial results demonstrate Grifols' resilience amid ongoing scrutiny, with the company positioning itself for sustained value creation through enhanced cash flow generation and deleveraging efforts. The positive earnings report may help restore investor confidence as the company continues to execute its strategic initiatives.